MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22…